The half-year financial statements for 2025 were subject to a limited review by the Company’s statutory auditors and were approved by the Board of Directors on October 15, 2025.

BioCryst Pharmaceuticals, Inc. acquires Astria Therapeutics for ~$700M, aiming to bolster its HAE portfolio. Learn more about ...

Headwater Gold Inc. (CSE: HWG, OTCQB: HWAUF) (the 'Company” or 'Headwater”) is pleased to announce that it has entered into a definitive agreement (the 'Agreement”) with a subsidiary of OceanaGold ...